Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularORALStandard

FLOLIPID

SIMVASTATIN

Standard Dose
20MG/5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Prescription
Summary

Approval overview FLOLIPID is listed in Drugs@FDA under application 206679 (NDA).

Review priority: 901 REQUIRED Marketing status: Prescription Active ingredient SIMVASTATIN Form and strength SUSPENSION;ORAL - 20MG/5ML Sponsor SALERNO PHARMS Submission history Latest submission status date: 2020-09-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview FLOLIPID is listed in Drugs@FDA under application 206679 (NDA). Review priority: 901 REQUIRED Marketing status: Prescription Active ingredient SIMVASTATIN Form and strength SUSPENSION;ORAL - 20MG/5ML Sponsor SALERNO PHARMS Submission history Latest submission status date: 2020-09-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: 901 REQUIRED

Interaction Notes

  • No interaction notes stored yet.